JP2011518790A - ポリクローナルタンパク質を製造する方法 - Google Patents

ポリクローナルタンパク質を製造する方法 Download PDF

Info

Publication number
JP2011518790A
JP2011518790A JP2011505362A JP2011505362A JP2011518790A JP 2011518790 A JP2011518790 A JP 2011518790A JP 2011505362 A JP2011505362 A JP 2011505362A JP 2011505362 A JP2011505362 A JP 2011505362A JP 2011518790 A JP2011518790 A JP 2011518790A
Authority
JP
Japan
Prior art keywords
protein
different
cells
cell
polyclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011505362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518790A5 (enExample
Inventor
アンネ・ボンゴー・トルストルップ
ラース・セゴー・ニールセン
ディートマル・ヴァイルグニィ
クリスティアン・ミューラー
フィン・セー・ヴィベルク
ヨナス・ヘイルスコヴ・グラヴェアセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servier Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of JP2011518790A publication Critical patent/JP2011518790A/ja
Publication of JP2011518790A5 publication Critical patent/JP2011518790A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011505362A 2008-04-23 2009-04-23 ポリクローナルタンパク質を製造する方法 Withdrawn JP2011518790A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4738908P 2008-04-23 2008-04-23
US61/047,389 2008-04-23
DKPA200800580 2008-04-23
DKPA200800580 2008-04-23
PCT/DK2009/050094 WO2009129814A1 (en) 2008-04-23 2009-04-23 Methods for manufacturing a polyclonal protein

Publications (2)

Publication Number Publication Date
JP2011518790A true JP2011518790A (ja) 2011-06-30
JP2011518790A5 JP2011518790A5 (enExample) 2012-05-31

Family

ID=40091979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505362A Withdrawn JP2011518790A (ja) 2008-04-23 2009-04-23 ポリクローナルタンパク質を製造する方法

Country Status (15)

Country Link
US (1) US20110117605A1 (enExample)
EP (1) EP2280998A1 (enExample)
JP (1) JP2011518790A (enExample)
KR (1) KR20110016899A (enExample)
CN (1) CN102007146A (enExample)
AU (1) AU2009240386A1 (enExample)
BR (1) BRPI0910454A2 (enExample)
CA (1) CA2722348A1 (enExample)
IL (1) IL208163A0 (enExample)
MX (1) MX2010011293A (enExample)
NZ (1) NZ588651A (enExample)
RU (1) RU2010147652A (enExample)
SG (1) SG189793A1 (enExample)
WO (1) WO2009129814A1 (enExample)
ZA (1) ZA201006765B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021528435A (ja) * 2018-06-22 2021-10-21 ゲンマブ エー／エス ２つ以上の異なる抗体の制御された混合物を産生するための方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735020A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
WO2012059857A2 (en) 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
JP6092782B2 (ja) * 2010-11-16 2017-03-08 エクセリミューン， インコーポレイテッド 組換えタンパク質の製造方法
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
WO2015095809A1 (en) * 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
DE102014220306B3 (de) * 2014-10-07 2015-09-03 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Automatisches Verfahren zur Beobachtung von Zellkulturwachstum
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7122974B2 (ja) 2016-05-11 2022-08-22 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 変異免疫グロブリン結合ポリペプチド
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
AU2018247916B2 (en) 2017-04-05 2025-04-24 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
EP3714035A4 (en) * 2017-11-22 2021-08-18 Culture Biosciences, Inc. AUTOMATION WORK CELL FOR FERMENTATION
US12071607B2 (en) * 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
CA3144125A1 (en) * 2019-07-16 2021-01-21 Haihong Sun Cell culture method based on high-density and continuous inoculation and use thereof
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
US20250263653A1 (en) * 2024-02-16 2025-08-21 Lanzatech, Inc. Methods and apparatus for the production of protein
KR102687341B1 (ko) * 2024-04-09 2024-07-23 주식회사 휴온스랩 온전한 형태의 히알루로니다제의 생산방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201097T3 (es) * 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
CN1437482A (zh) * 2000-05-26 2003-08-20 西福根有限公司 用于治疗变态反应的重组的或纯化的多克隆抗体
US6849259B2 (en) * 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
WO2002044361A2 (en) * 2000-11-28 2002-06-06 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
NZ537277A (en) * 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EA013225B1 (ru) * 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
CA2535489C (en) * 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
JP4926054B2 (ja) * 2004-07-20 2012-05-09 シムフォゲン・アクティーゼルスカブ 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法
ES2332524T3 (es) * 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007065433A2 (en) * 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
BRPI0812091A2 (pt) * 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021528435A (ja) * 2018-06-22 2021-10-21 ゲンマブ エー／エス ２つ以上の異なる抗体の制御された混合物を産生するための方法
JP2024109884A (ja) * 2018-06-22 2024-08-14 ジェンマブ エー／エス ２つ以上の異なる抗体の制御された混合物を産生するための方法

Also Published As

Publication number Publication date
CA2722348A1 (en) 2009-10-29
EP2280998A1 (en) 2011-02-09
NZ588651A (en) 2012-04-27
KR20110016899A (ko) 2011-02-18
SG189793A1 (en) 2013-05-31
CN102007146A (zh) 2011-04-06
RU2010147652A (ru) 2012-05-27
IL208163A0 (en) 2010-12-30
ZA201006765B (en) 2012-03-28
US20110117605A1 (en) 2011-05-19
WO2009129814A1 (en) 2009-10-29
AU2009240386A1 (en) 2009-10-29
BRPI0910454A2 (pt) 2018-03-27
MX2010011293A (es) 2010-12-20

Similar Documents

Publication Publication Date Title
US20110117605A1 (en) Methods for Manufacturing a Polyclonal Protein
AU2023200660B2 (en) Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
CN108368505B (zh) 改善的flare(流式细胞术减弱报道蛋白表达)技术用于快速批量分选
AU734800B2 (en) Production of a multimeric protein by cell fusion method
KR20100017923A (ko) 재조합 폴리클로날 단백질의 제조 방법
TW200907059A (en) Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells
US20240239871A1 (en) Hypersialylating cells
KR20080113279A (ko) 인간 태아 간 줄기 세포가 주입된 면역결핍 동물에서 항체를 생성시키는 방법
CN102498212B (zh) Cho/cert细胞系
TW201402815A (zh) 生產細胞株增強子
KR20250079008A (ko) 신규 트랜스포사제 시스템
EA043386B1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
HK1167429A (en) Cho/cert cell lines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120328

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130805